Verinata develops non-invasive tests to identify early fetal chromosomal abnormalities using proprietary technologies.
Verinata Health CEO Caren Mason said reaching this milestone of CAP accreditation sets Verinata apart as having met the CAP quality standards required to ensure accuracy and reliability of their testing process.
"We are applying the same stringent quality principles to every aspect of our business as we prepare for the commercial launch of our first non-invasive prenatal diagnostic test in the first quarter of 2012," Mason said.
